Prescribing Combined Oral Contraceptives: Estrogen and Progestin Dosing
Start with a low-dose combined oral contraceptive containing 30-35 μg ethinyl estradiol paired with levonorgestrel or norgestimate. This represents the evidence-based first-line approach for most patients, balancing efficacy, safety, and tolerability 1.
Estrogen Component: Dose Matters for Safety
The estrogen dose directly impacts thrombotic risk. Use pills containing ≤35 μg ethinyl estradiol as your first-line option 1, 2. Here's why:
- Pills with <50 μg ethinyl estradiol have dramatically lower rates of myocardial infarction, stroke, and venous thromboembolism compared to higher-dose formulations 3
- The baseline VTE risk increases from 1 per 10,000 woman-years to 3-4 per 10,000 with low-dose COCs—still far lower than pregnancy-associated VTE risk of 10-20 per 10,000 1, 4
- Avoid 20 μg formulations initially despite their theoretical safety advantage, as they cause significantly higher rates of breakthrough bleeding and early discontinuation, potentially leading to unintended pregnancy when patients switch to less effective methods 5, 6
Alternative Estrogens
Natural estrogens (17β-estradiol, estradiol valerate) are now available and may offer advantages in specific populations, though ethinyl estradiol remains the standard 2, 7.
Progestin Selection: Start with Second-Generation
Levonorgestrel and norgestimate are your first-line progestins 1, 8. The evidence supporting this choice:
- Second-generation progestins (levonorgestrel, norethisterone) combined with 30-35 μg ethinyl estradiol have the most favorable safety profile 8
- Third-generation progestins (desogestrel, gestodene) and newer progestins (drospirenone, cyproterone acetate) carry 2-fold higher VTE risk compared to levonorgestrel, with odds ratios ranging from 2.2 to 6.6 9, 2, 3
- Antiandrogenic progestins may negatively impact sexual arousal, lubrication, and orgasm 10
Formulation Type: Keep It Simple
Prescribe monophasic pills initially 1. They contain the same hormone dose in each active pill, making them easier to use and allowing for flexible extended-cycle regimens if needed. Switch to alternative formulations only if the patient experiences persistent adverse effects.
Critical Contraindications to Screen For
COCs are absolutely contraindicated in patients with 1, 4:
- Migraines with aura or focal neurologic symptoms
- History of thromboembolism or known thrombophilia (Factor V Leiden, antiphospholipid antibodies, protein C/S deficiency)
- Severe uncontrolled hypertension (≥160/100 mmHg)
- Active or complicated liver disease
- Complicated valvular heart disease
- Diabetes with vascular complications
- Smoking in women ≥35 years old
For patients with antiphospholipid antibodies, even without clinical events, estrogen-containing contraceptives are absolutely contraindicated due to dramatically increased thrombosis risk 9.
Special Populations Requiring Progestin-Only Methods
Switch to progestin-only contraception or IUDs in 9:
- Active SLE with moderate-to-severe disease activity or nephritis
- Any patient with positive antiphospholipid antibodies
- History of venous or arterial thrombosis
- Documented thrombophilia
Practical Prescribing Algorithm
- Screen for absolute contraindications (see above)
- Start with: 30-35 μg ethinyl estradiol + levonorgestrel or norgestimate, monophasic formulation
- Counsel on: 7-day backup contraception needed initially; transient side effects (irregular bleeding, headache, nausea) typically resolve
- Follow-up: 1-3 months to address persistent adverse effects or adherence issues 1, 4
- If breakthrough bleeding persists: Consider switching progestin type or extending cycles rather than increasing estrogen dose
- Prescribe: Up to 1 year supply at once to improve adherence 4
Common Pitfall to Avoid
Do not automatically prescribe 20 μg formulations thinking "lower is safer." While theoretically advantageous for VTE risk, these pills cause significantly more breakthrough bleeding and discontinuation 5. When patients discontinue due to bleeding, they often switch to less effective methods or no method, ultimately increasing unintended pregnancy risk—which carries far greater morbidity than the marginal VTE risk difference 6.
The 30-35 μg dose with second-generation progestins represents the optimal balance of efficacy, cycle control, and safety for most patients.